| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Neuroscience |
1 Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
-G and PGD2-EA, but not PGE2-EA or PGF2-EA, also increased the frequency of mIPSCs. The eCB-derived prostanoid-induced responses appeared to be different from those of corresponding arachidonic acid-derived prostanoids, implying that these effects are not mediated via known prostanoid receptors. We further discovered that the inhibition of COX-2 activity reduced inhibitory synaptic activity and augmented depolarization-induced suppression of inhibition (DSI), whereas the enhancement of COX-2 augmented the synaptic transmission and abolished DSI. Our results, which show that COX-2 oxidative metabolites of eCBs exert opposite effects to their parent molecules on inhibitory synaptic transmission, suggest that alterations in COX-2 activity will have significant impact on endocannabinoid signalling in hippocampal synaptic activity.
(Received 17 January 2006;
accepted after revision 14 February 2006;
first published online 16 February 2006)
Corresponding author C. Chen: Neuroscience Center of Excellence, Louisiana State University Health Sciences Center, 2020 Gravier Street, Suite D, New Orleans, LA 70112, USA. Email: cchen{at}lsuhsc.edu
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Endocannabinoids are involved in a variety of physiological and pathological processes in mammalian tissue via CB1 and CB2 receptors (Hajos & Freund, 2002a; Freund et al. 2003; Piomelli, 2003; Alger, 2004; Howlett et al. 2004; Di Marzo et al. 2004; Patrignani et al. 2005). In the brain, the main focus for eCBs in synaptic signalling is on the presynaptic CB1 receptor-mediated regulation of inhibitory synaptic transmission. However, the role of eCB-derived, COX-2-oxygenated prostanoids in synaptic signalling is unknown. We observed previously that PGE2, a major COX-2 oxidative metabolite of AA, modulates hippocampal synaptic transmission and plasticity (Chen et al. 2002; Chen & Bazan, 2005a; Sang et al. 2005). Here we report that COX-2 oxidative metabolites of 2-AG and AEA induced opposite effects to their precursors on inhibitory synaptic transmission via CB1- and prostanoid receptor-independent mechanisms. Our data suggest that COX-2-generated novel prostanoids, PG-Gs or PG-EAs, represent unique signalling mediators with potent activities distinct from their parent molecules, and exert biological responses extending the range of actions of their related PGs, implying that alterations in COX-2 activity will significantly influence endocannabinoid signalling in hippocampal synaptic function.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
All experiments were carried out according to the guidelines approved by the Institutional Animal Care and Use Committee of Louisiana State University Health Sciences Center.
Primary hippocampal neurons were cultured as described before with some modifications (Chen & Bazan, 1999; Zhu et al. 2005; Sang et al. 2005). Briefly, mouse (FVB) pups (postnatal days 0–1) were rapidly decapitated, and hippocampi were immediately dissected out from the brain. The tissue was incubated in oxygenated trypsin for 10 min at 37°C and then mechanically triturated. Cells were spun down and resuspended in Neurobasal–B27 medium (Invitrogen) supplemented with 0.5 mML-glutamine, penicillin–streptomycin and 25 µM glutamate. Cells (1 x 106) were loaded into poly D-lysine-coated 35 mm culture dishes. One-third to one-half of the culture medium without glutamate was changed every 2–3 days. In some experiments where COX-2 activity was inhibited or enhanced, neurons were treated with interleukin-1ß (IL-1ß; Sigma, St Louis, MO, USA) or NS398 (Sigma) for 12 h. Cultures were used between 14 and 21 days in vitro.
Electrophysiological recordings
Miniature inhibitory postsynaptic currents (mIPSCs) were recorded in hippocampal neurons in culture under voltage clamp using an Axopatch-200B amplifier. Recording pipettes (4–5 M
) were pulled from borosilicate glass with a micropipette puller (Sutter Instrument Co.). The internal pipette solution contained (mM): 115.0 caesium gluconate, 15.0 CsCl, 4.0 NaCl, 10.0 Hepes, 0.5 EGTA, 4.0 Mg2ATP, and 0.5 Na2GTP (pH 7.25 with CsOH). The membrane potential was held at –70 mV. The external solution contained (mM): 130.0 NaCl, 2.5 KCl, 1.0 MgCl2, 10.0 Hepes, 1.25 NaH2PO4, 2.0 CaCl2, 25.0 glucose (pH 7.4 with NaOH). To isolate mIPSCs, TTX (0.5–1 µM), a voltage-gated Na+ channel blocker, 6,7-dinitro-quinoxaline-2,3-dione (DNQX; 10 µM), an AMPA receptor blocker, and D-aminophosphonovalerate (APV; 50 µM), an NMDA receptor blocker, were included in the external solution. All experiments were performed at room temperature (22–24°C). The frequency, amplitude and kinetics were analysed using the MiniAnalysis program.
Chemicals and drugs
2-AG, AEA, PG-Gs (PGE2-G, PGD2-G and PGF2-G) and PG-EAs (PGE2-EA, PGD2-EA and PGF2-EA) were purchased from Cayman Chemical (Ann Arbor, MI, USA). These chemicals were dissolved in ethanol to make stock solutions at concentrations of 20 mM and distributed in small vials. To prevent the oxidation of lipids, the air in vials was expelled with nitrogen gas before being stored in a –80°C freezer. To ensure that these bioactive lipids were effective, the lipids were usually used within a very short period of time as soon as the vials were opened. In addition, we always used the lipids from different batches to ensure that the results could be duplicated. The stock solutions in the vials were diluted with the external solution to desired concentrations just before recordings. The drug solutions were applied by lowering the pipette (
50 µm of tip size) to within 30–50 µm of the recorded cell, and the application was terminated by removal of the pipette from the bathing medium. 2-Aminoethoxydiphenyl borane (2-APB), PD98059 (PD), chelerythrine and KT5720 (Tocris, Ellisville, MO, USA), NS398 and SR141716 (provided by Chemical Synthesis and Drug Supply Program, the National Institute of Mental Health) were dissolved in DMSO to make up stock solutions at concentrations of 50–100 mM, and applied through bath perfusion. All other drugs and chemicals were obtained from Sigma unless stated otherwise. To rule out potentially non-specific effects of the solvents, the same amount of ethanol or DMSO was included in the control external solution.
Data analysis
Data are presented as means ±S.E.M. Unless stated otherwise, Student's t test was used for comparisons of before and after drug applications, analysis of variance (ANOVA) was used for between-group comparisons, and the Kolmogorov-Smirnov test was used for comparisons of mIPSC distribution. Differences were considered significant when P < 0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To address whether COX-2 oxidative metabolites of eCBs participate in synaptic signalling, we recorded mIPSCs in primary cultured hippocampal neurons. As shown in Fig. 1A, 2-AG (1 µM) significantly reduced the frequency of mIPSCs to 54.3 ± 4.4% of baseline (n= 6, P < 0.01) at 10 min following the application of 2-AG, but not the amplitude (92.1 ± 4.8% of baseline, n= 6, P > 0.05). The effect was reversible following 20 min of wash (90.7 ± 12.6% of baseline, n= 6, P > 0.05). In contrast to the effect of 2-AG, PGE2-G, a major COX-2 oxidative metabolite of 2-AG, at a concentration of 30 µM significantly increased the frequency of mIPSCs to 180.4 ± 16.3% of baseline (n= 7, P < 0.01), while it did not induce a significant change in the amplitude of mIPSCs (97.1 ± 1.7% of baseline, n= 7, P > 0.05). The PGE2-G-induced enhancement of the mIPSC frequency exhibited dose dependence (Fig. 1B). The EC50 for the PGE2-G-induced effect was 1.71 ± 0.05 µM. Similar to that of 2-AG, the PGE2-G-induced augmentation of mIPSC frequency was also reversible after 20 min of wash (100.7 ± 10.4% of baseline, n= 7, P > 0.05). These results indicate that PGE2-G, the COX-2 oxidative metabolite of 2-AG, augmented hippocampal inhibitory synaptic transmission, an effect opposite to its precursor.
|
PGE2-EA does not induce an effect on mIPSCs
To determine whether COX-2 oxidative metabolites of AEA are involved in hippocampal synaptic signalling, we recorded synaptic responses in the presence of PGE2-EA, a major COX-2 oxidative metabolite of AEA (Ross et al. 2002). While AEA (5 µM) significantly induced a reversible reduction in the frequency of mIPSCs at 10 min following the application of AEA (64.2 ± 4.0% of baseline n= 7, P < 0.01), PGE2-EA (30 µM) did not elicit a detectable response in either the frequency (100.1 ± 4.3% of baseline, n= 5, P > 0.05) or amplitude (98.6 ± 3.7% of baseline, n= 5, P > 0.05) of mIPSCs (Fig. 2). These data show that PGE2-EA does not have an effect on GABAergic synaptic transmission in primary cultured hippocampal neurons.
|
In the brain, the eCB-induced effect is mainly mediated by the CB1 receptor (CB1R; Felder, 1998; Sullivan, 2000; Wilson & Nicoll, 2001, 2002; Hajos & Freund, 2002a,b; McAllister & Glass, 2002; Freund et al. 2003; Piomelli, 2003; Hajos et al. 2004; Isokawa & Alger, 2005). To determine whether the PGE2-G-induced enhancement of mIPSCs is mediated by the CB1R, we examined the effects of 2-AG, AEA and PGE2-G on mIPSCs in the presence of SR141716 (SR), a CB1R antagonist (provided by the National Institute of Mental Health Chemical Synthesis and Drug Supply Program). As indicated in Fig. 3A and B, bath application of SR (1 µM) for 30 min blocked 2-AG and AEA-induced reduction in the frequency of mIPSCs (111.4 ± 14.1% of baseline, n= 3, P > 0.05; and 92.3 ± 13.9% of baseline, n= 4, P > 0.05, respectively). However, PGE2-G still augmented the frequency of mIPSCs in neurons pre-treated with SR (1 µM) for 30 min (182.5 ± 15.1% of baseline, n= 7, P < 0.01) (Fig. 3C). These results indicate that the PGE2-G-induced effect on synaptic transmission is not mediated via the CB1 receptor, and provide further evidence that the PGE2-G-induced response is different from its parent molecule.
|
Since PGE2-G and PGE2-EA, major COX-2 oxidative metabolites of 2-AG and AEA, produced distinct effects on mIPSCs in cultured hippocampal neurons, we then decided to examine the effects of other COX-2 oxidative metabolites of 2-AG and AEA on inhibitory synaptic transmission. We individually applied PGD2-G, PGF2-G, PGD2-EA and PGF2-EA in cultured hippocampal neurons. As shown in Table 1, PGD2-G (30 µM), PGF2-G (30 µM) and PGD2-EA (30 µM) significantly augmented the frequency of mIPSCs (158.7 ± 10.5% of baseline, n= 6, P < 0.01; 140.9 ± 7.2% of baseline, n= 10, P < 0.01; 134.6 ± 7.0% of baseline, n= 6, P < 0.01, respectively), but not the amplitude. Similar to that of PGE2-EA, PGF2-EA (30 µM) did not induce significant effects on the frequency and amplitude of mIPSCs. These results reveal that these novel prostanoids may be involved in hippocampal synaptic signalling. However, it was not clear which receptor(s) mediate(s) these novel prostanoid-induced synaptic responses. Indeed, recent evidence indicates that eCB metabolites resulting from the COX-2 oxygenation may be novel signal mediators (Kozak et al. 2004), and may have biological efficacy through prostanoid receptor-dependent and -independent mechanisms (Ross et al. 2002; Matias et al. 2004; Nirodi et al. 2004). Because there are very few prostanoid receptor antagonists commercially available, at least for PGE2 receptors, we decided to directly apply AA-derived PGs (PGE2, PGD2 and PGF2) in hippocampal neurons to determine their effects on mIPSCs, and compared the effects with those of eCB-derived prostanoids. Interestingly, application of PGE2 (5 µM) and PGD2 (5 µM) significantly decreased the frequency of mIPSCs (81.9 ± 7.1% of baseline, n= 9, P < 0.01; 58.3 ± 4.4% of baseline, n= 7, P < 0.01, respectively), an effect opposite to that of PGE2-G and PGD2-G, eCB-derived prostanoids. Meanwhile, we observed that PGF2 (5 µM) did not induce significant changes in the frequency and amplitude of mIPSCs. These results demonstrate that the eCB-derived prostanoid-induced effect on mIPSCs is different from that of AA-derived prostanoids, implying that there may be undefined receptors rather than prostanoid receptors mediating the responses.
|
A recent report has shown that PGE2-G mobilizes intracellular calcium, triggers inositol 1,4,5-trisphosphate (IP3) synthesis, and activates protein kinase C (PKC) in RAW264.7 macrophage cells (Nirodi et al. 2004). To probe the possible signal transduction pathway for the PGE2-G-induced response in hippocampal synaptic signalling, we applied 2-APB, an IP3 inhibitor, PD98059 (PD), a mitogen-activated protein kinase (MAPK) inhibitor, chelerythrine, a PKC inhibitor, and KT5720 (KT), a PKA inhibitor. As illustrated in Fig. 4, bath application of 2-APB (20 µM) for 30 min significantly attenuated the PGE2-G (10 µM)-induced increase in mIPSC frequency (from 171.9 ± 11.5% to 143.5 ± 5.7% of baseline, n= 8, P < 0.05). Similarly, PD (20 µM) reduced the enhancement to 139.7 ± 6.5% (n= 7, P < 0.05). However, chelerythrine (1 µM) or KT (1 µM) did not affect the PGE2-G (10 µM)-induced increase in mIPSC frequency. These data provided evidence that the PGE2-G-induced enhancement of synaptic transmission may be mediated via IP3 and MAPK pathways.
|
If COX-2 plays an important role in the metabolism of eCBs, and its oxidative metabolites of eCBs participate in synaptic signalling, then, up- or down-regulation of COX-2 expression or activity should alter eCB signalling in synaptic transmission. To test this hypothesis, neurons were treated with NS398, a selective COX-2 inhibitor (Chen et al. 2002; Chen & Bazan, 2005a; Sang et al. 2005), and IL-1ß, a known COX-2 inducer. As indicated in Fig. 5A, the basal inhibitory synaptic transmission was significantly reduced in neurons treated with NS398 (20 µM) for 12 h (frequency: 36.7 ± 9.4% of control, n= 7, P < 0.05; amplitude: 71.1 ± 3.6% of control, n= 7, P < 0.05). The NS398-induced reduction of mIPSCs was not blocked by 1 µM SR (frequency: 42.6 ± 7.7% of control, n= 7, P < 0.01; amplitude: 81.7 ± 2.9%, n= 7, P < 0.05). There were no significant differences in the reductions of the frequency and amplitude of mIPSCs between the absence and presence of SR in NS398-treated neurons. This phenomenon is in harmony with results reported by others (Kim & Alger, 2004). To test whether the COX-2 inhibition-induced reduction of mIPSCs resulted from accumulated AA, we examined the effect of AA on mIPSCs. AA (10 µM) significantly reduced the frequency of mIPSCs to 57.5 ± 8.0% (P < 0.01, n= 6) of the baseline, but not the amplitude (97.3 ± 3.2% of the baseline, P > 0.05, n= 6). The AA-induced decrease in the frequency of mIPSCs was not inhibited by SR (60.3 ± 5.4%, P < 0.01; n= 5). In contrast, the frequency of mIPSCs was significantly elevated in neurons treated with IL-1ß (20 ng ml–1) for 12 h (184.8 ± 32.7% of control, n= 9, P < 0.05), but not the amplitude (101.4 ± 4.3% of control, n= 9, P > 0.05). Application of SR failed to block the IL-1ß-induced potentiation of the frequency (189.4 ± 25.1% of control, n= 6, P < 0.05). These results indicate that alterations in basal mIPSCs in neurons treated with NS398 or IL-1ß may not be mediated by CB1R. To confirm that the IL-1ß-induced enhancement of mIPSCs may be due to COX-2 oxidative metabolites of eCBs, we applied 2-APB and PD to hippocampal neurons treated with IL-1ß (20 ng ml–1) for 12 h. We found that both IP3 and MAPK inhibitors significantly attenuated the IL-1ß-induced enhancement of mIPSC frequency by 58.8 ± 5.7% (n= 8, P < 0.05) and 52.0 ± 6.3% (P < 0.01, n= 10), respectively. These data indicate that the COX-2 up-regulation-induced enhancement of inhibitory synaptic activity is probably mediated by oxidative metabolites of 2-AG.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In addition to the well-studied hydrolytic modes of eCB metabolism, these bioactive lipids are also susceptible to oxidative metabolism by a number of fatty acid oxygenases, including cyclooxygenases, lipoxygenases, and cytochrome P450s known to be involved in eicosanoid production from AA (Kozak et al. 2004). It has recently been demonstrated that COX-2 oxygenates 2-AG and AEA (Yu et al. 1997; So et al. 1998; Kozak et al. 2000, 2001). However, the biological consequences of this connection have only begun to be investigated. The eCB-derived COX-2 oxygenated products might represent unique signal mediators with potent activities distinct from their precursors and corresponding AA-derived prostanoids (Kozak et al. 2004; Patrignani et al. 2005). We found in the present study that PGE2-G, a main COX-2 oxidative metabolite of 2-AG, significantly increased the frequency of mIPSCs, and the increase was not mediated via the CB1R. Meanwhile, PGD2-G, PGF2-G and PGD2-EA also increased the frequency of mIPSCs, but not PGE2-EA and PGF2-EA. Our findings suggest that some COX-2 oxidative metabolites of eCBs act as signalling molecules and modulate synaptic transmission, while others may not serve as signal modulators in hippocampal synaptic transmission, but may participate in some undefined functions.
At present, little is known about the mechanisms of PG-G- and PG-EA-induced functional roles in hippocampal synaptic transmission (Kozak et al. 2004; Chen & Bazan, 2005b). It has been proposed that these novel lipids may have biological efficacy through prostanoid receptor-dependent and -independent mechanisms (Ross et al. 2002; Kozak et al. 2004; Matias et al. 2004; Nirodi et al. 2004). For instance, a recent study shows that PGE2-EA has a similar profile of action to that of PGE2 in that it binds to PGE2 receptors (EP) (Ross et al. 2002). However, our results indicate that PG-G- and PG-EA-induced effects on mIPSCs are different from those induced by corresponding AA-derived PGs, suggesting that the eCB-derived prostanoid-induced effects are not mediated via known prostanoid receptors. Recent evidence also shows that the PGE2-G triggers intracellular Ca2+ mobilization via IP3 and PKC pathways in RAW264.7 macrophage cells (Nirodi et al. 2004). However, we observed that the PGE2-G-induced increase in the frequency of mIPSCs is attenuated by IP3 and MAPK inhibitors, but not by a PKC or protein kinase A (PKA) inhibitor in hippocampal neurons in culture. This discrepancy between our observations and others is probably due to the different preparations used (Nirodi et al. 2004).
Since COX-2 metabolizes 2-AG and AEA, and eCB-derived prostanoids exert opposite effects to that of 2-AG and AEA on inhibitory synaptic transmission, it is possible that alterations in COX-2 expression or activity would significantly influence the amount of eCBs available, resulting in changes in synaptic activity. This postulation has been confirmed by a recent study in which COX-2 inhibition augments DSI in the hippocampus (Kim & Alger, 2004). Our present study provides further evidence that the inhibition of COX-2 retards the inactivation of eCBs, thereby raising the eCB levels and promoting the eCB-mediated responses, whereas the enhancement of COX-2 accelerates the metabolism of eCBs, thereby lowering the eCB levels and reducing the eCB-mediated responses. Interestingly, we observed that NS398 significantly decreases the basal inhibitory synaptic activity in terms of frequency and amplitude of mIPSCs, and the decrease appears not to be mediated by the CB1R, similar to the findings of Kim & Alger (2004). While the mechanisms by which the COX-2 inhibition induces reduction in basal inhibitory synaptic transmission are still not completely understood (Kim & Alger, 2004), we observed in the present study that AA (10 µM) significantly inhibited the frequency of mIPSCs, and the inhibition was not blocked by SR. This information suggests that accumulated AA during the COX-2 inhibition may be, at least in part, responsible for the reduced synaptic activity in neurons treated with the COX-2 inhibitor. On the other hand, the IL-1ß-induced increase in the basal inhibitory synaptic transmission probably results from the reduced eCBs, and elevated their COX-2 oxidative metabolites, PG-Gs and PG-EAs. This assumption was supported by the experiments where SR failed to block the IL-1ß-induced enhancement of mIPSCs, and the IP3 and MAPK inhibitors significantly reduced the frequency of mIPSCs in neurons treated with IL-1ß. These observations suggest that there was, at least, an increased amount of PGE2-G in the culture where COX-2 expression was enhanced by IL-1ß.
Our results provide evidence that eCB-derived COX-2-oxygenated prostanoids are probably a new class of signalling mediator involved in hippocampal synaptic transmission. This means that COX-2 plays a central role in metabolizing AA and eCBs and generating AA- and eCB-derived prostanoids. Thus, the excessive expression of COX-2 or enhanced COX-2 activity resulting from inflammation, traumatic injury, epilepsy or degenerative processes will have significant impact on eCBs, AA- and eCB-derived prostanoid signalling in synaptic activity, indicating that unravelling this important signal transduction pathway will be of substantial significance in our understanding of the roles of COX-2-mediated events in physiological, pharmacological and pathological functions.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Bazan NG & Flower RJ (2002). Lipid signals in pain control. Nature 420, 135–138.[CrossRef][Medline]
Chandrasekharan
NV, Dai
H, Roos
KLT, Evanson
NK, Tomsik
J, Elton
TS
&
Simmons
DL (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A
99, 13926–13931.
Chen C & Bazan NG (1999). Platelet-activating factor inhibits ionotropic GABA receptor activity in cultured hippocampal neurons. Neuroreport 10, 3831–3835.[Medline]
Chen
C
&
Bazan
NG (2005a). Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J Neurophysiol
93, 929–941.
Chen C & Bazan NG (2005b). Lipid signaling: Sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 77, 65–76.[CrossRef][Medline]
Chen
C, Magee
JC
&
Bazan
NG (2002). Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol
87, 2851–2857.
Di Marzo V, Bifulco M & De Petrocellis L (2004). The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3, 771–784.[CrossRef][Medline]
Felder CC (1998). Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol 38, 179–200.[CrossRef][Medline]
Freund
TF, Katona
I
&
Piomelli
D (2003). Role of endogenous cannabinoids in synaptic signaling. Physiol Rev
83, 1017–1066.
Hajos N & Freund TF (2002a). Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. Chem Phys Lipids 121, 73–82.[CrossRef][Medline]
Hajos N & Freund TF (2002b). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacol 43, 503–510.[CrossRef][Medline]
Hajos N, Kathuria S, Dinh T, Piomelli D & Freund TF (2004). Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur J Neurosci 19, 2991–2996.[CrossRef][Medline]
Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE & Porrino LJ (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacol 47 (Suppl. 1), 345–358.[CrossRef][Medline]
Isokawa
M
&
Alger
BE (2005). Retrograde endocannabinoid regulation of GABAergic inhibition in the rat dentate gyrus granule cell. J Physiol
567, 1001–1010.
Kaufmann
WE, Worley
PF, Pegg
J, Bremer
M
&
Isakson
P (1996). COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A
93, 2317–2321.
Kim J & Alger BE (2004). Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. Nat Neurosci 7, 697–698.[CrossRef][Medline]
Kozak
KR, Crews
BC, Morrow
JD, Wang
LH, Ma
YH, Weinander
R, Jakobsson
PJ
&
Marnett
LJ (2002). Metabolism of the endocannabinoid, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem
277, 44877–44885.
Kozak KR, Prusakiewicz JL & Marnett LJ (2004). Oxidative metabolism of endocannabinoids by COX-2. Curr Pharm Des 10, 659–667.[CrossRef][Medline]
Kozak
KR, Prusakiewicz
JL, Rowlinson
SW, Schneider
C
&
Marnett
LJ (2001). Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and vivo. J Biol Chem
276, 30072–30077.
Kozak KR, Rowlinson SW & Marnett LJ (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glycerol prostaglandins by COX-2. J Biol Chem 27, 33744–33749.
McAllister SD & Glass M (2002). CB1 and CB2 receptor-mediated signaling: a focus on endocannabinoids. Prostagland Leuk Essen Fatty Acid 66, 161–171.[CrossRef]
Matias
I, Chen
J, Petrocellis
LD, Bisogno
T, Ligresti
A, Fezza
F, Krauss
AHP, Shi
L, Protzman
CE, Li
C, Liang
Y, Niexes
L, Kedzie
KM, Burk
RM, Marzo
VD
&
Woodward
DF (2004). Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther
309, 745–757.
Nirodi
CS, Crews
BC, Kozak
KR, Morrow
JD
&
Marnett
LJ (2004). The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells. Proc Natl Acad Sci U S A
101, 1840–1845.
Patrignani P, Tacconelli S, Sciulli MG & Capone ML (2005). New insight into COX-2 biology and inhibition. Brain Res Rev 48, 352–359.[CrossRef][Medline]
Piomelli D (2003). The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 4, 873–884.[CrossRef][Medline]
Ross
RA, Craib
SJ, Stevenson
LA, Pertwee
RG, Henderson
A, Toole
J
&
Ellington
HC (2002). Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther
301, 900–907.
Sang
N, Zhang
J, Marcheselli
V, Bazan
NG
&
Chen
C (2005). Postsynaptically synthesized prostaglandin E2 modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J Neurosci
25, 9858–9870.
So
OY, Scarafia
LE, Mak
AY, Callan
OH
&
Swinney
DC (1998). The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J Biol Chem
273, 5801–5807.
Sullivan
JM (2000). Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem
7, 132–139.
Vane JR, Bakhle YS & Botting RM (1998). Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38, 97–120.[CrossRef][Medline]
Wilson RI & Nicoll RA (2001). Endogenous cannabinoids mediate retrograde signaling at hippocampal synapse. Nature 410, 588–592.[CrossRef][Medline]
Wilson
RI
&
Nicoll
RA (2002). Endocannabinoids signaling in the brain. Science
296, 678–681.
Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA & Worley PF (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11, 371–386.[CrossRef][Medline]
Yamasaki
M, Hashimoto
K
&
Kano
M (2006). Miniature synaptic events elicited by presynaptic Ca2+ rise are selectively suppressed by cannabinoid receptor activation in cerebellar Purkinje cells. J Neurosci
26, 86–95.
Yu
M, Ives
D
&
Ramesha
CS (1997). Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem
272, 21181–21186.
Zhu P, Genc A, Zhang X, Zhang J, Bazan NG & Chen C (2005). Heterogeneous expression and regulation of PGE2 receptors in the hippocampus. J Neurosci Res 81, 817–826.[CrossRef][Medline]
|
Acknowledgements |
|---|
This article has been cited by other articles:
|
|
 |
|
  C. A. Rouzer and L. J. Marnett Non-redundant Functions of Cyclooxygenases: Oxygenation of Endocannabinoids J. Biol. Chem., March 28, 2008; 283(13): 8065 - 8069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sang and C. Chen Lipid Signaling and Synaptic Plasticity Neuroscientist, October 1, 2006; 12(5): 425 - 434. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
